Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959448 · ClinicalTrials.gov registry record
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
A clinical trial of Chronic Rhinosinusitis With Nasal Polyposis, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- 717
- Enrollment target
- 20
- Study locations
NCT04959448 is a study of Chronic Rhinosinusitis With Nasal Polyposis that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 717 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT04959448, a study of Chronic Rhinosinusitis With Nasal Polyposis, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 717 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of the study are: * To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change over-time. * To characterize patients who receive DUPIXENT® for CRSwNP in a real-world setting with respect to their medical history, demographic and disease characteristics, and type 2 comorbidities The secondary objectives of the study are: * To characterize real-world utilization of DUPIXENT® for patients with CRSwNP * To collect patient and physician global assessment of disease severity and treatment satisfaction for patients receiving DUPIXENT® for CRSwNP * To collect long-term safety data for patients receiving DUPIXENT® for CRSwNP
Conditions Studied
Interventions
- DRUG DUPIXENT®
Study Locations (20)
California
- The Allergy and Rheumatology Medical Clinic - La Jolla
- ARK Clinical Research - Long Beach
- Scripps Health - Scripps Clinic Carmel Valley - San Diego
- Breathe Clear Institute - Torrance
- Allergy & Asthma Clinical Research - Walnut Creek
Florida
- AADRS Clincial Research Center - Coral Gables
- University of Florida - Gainesville
- Damask Physicians Group - Lake Mary
- University of South Florida - Tampa
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- University of Illinois - Chicago
- The University of Chicago Medical Center UCMC Duchossois Center for Advanced Medicine DCAM - Chicago
- Asthma & Allergy Center of Chicago - Oak Park
Georgia
- Emory University Hospital Midtown - Atlanta
- IACT Health - Columbus
Alabama
- Excel ENT of Alabama - Birmingham
Arizona
- Medical Research of Arizona, a division of Allergy, Asthma & Immunology Associates - Scottsdale
Idaho
- Treasure Valley Medical Research - Boise
Indiana
- Indiana University Health - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 717 participants |
| Start Date | 2021-08-12 |
| Est. Completion | 2027-03-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04959448
The ClinicalTrials.gov registry entry for NCT04959448 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 717 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyposis appearing as the primary indexed condition, and to 1 intervention - of which DUPIXENT® is the first listed.
NCT04959448 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT04959448 about?
NCT04959448 is a clinical study titled "Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)". The primary objectives of the study are: * To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, ...
What is the current status of trial NCT04959448?
This trial is currently active not recruiting. The enrollment target is 717 participants. The study started on 2021-08-12. Estimated completion is 2027-03-25.
What conditions does trial NCT04959448 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyposis.
What interventions are being tested in trial NCT04959448?
The interventions under investigation include: DUPIXENT® (DRUG).
Who is sponsoring clinical trial NCT04959448?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04959448 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.